Related Experiment Video

Updated: Jun 12, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Anti-CD3 monoclonal antibody treatment in newly diagnosed Type 1 diabetes patients: a hypothetical modelling analysis

J Smith-Palmer1, B H Curtis, K S Boye

  • 1IMS Health, Allschwil, Switzerland. jsmith-palmer@ch.imshealth.com

Diabetic Medicine : a Journal of the British Diabetic Association
|June 16, 2010
PubMed
Abstract

Insights

Hypothetical anti-CD3 monoclonal antibody therapy may improve long-term outcomes for new Type 1 diabetes cases. This treatment could increase life expectancy and quality-adjusted life expectancy compared to standard insulin therapy.

Area of Science:

  • Immunology
  • Endocrinology
  • Diabetology

Background:

  • Limited clinical data exist for anti-CD3 monoclonal antibody therapies in Type 1 diabetes.
  • These therapies are hypothesized to impact glycaemic control, insulin secretion, and hypoglycaemia.
  • There is a need for empirical evidence on long-term outcomes.

Purpose of the Study:

  • To estimate the potential long-term clinical outcomes of anti-CD3 monoclonal antibody treatment in newly diagnosed Type 1 diabetes.
  • To assess the impact on glycaemic control, life expectancy, and quality of life.
  • To provide data in the absence of extensive clinical trials.

Main Methods:

  • Utilized a validated computer simulation model of Type 1 diabetes.
  • Simulations were based on a hypothetical US cohort, literature, and expert opinion.
  • A 60-year time horizon was used, incorporating published quality-of-life utility values.

Main Results:

  • A projected increase in undiscounted life expectancy of 0.43 years.
  • An estimated increase in quality-adjusted life expectancy of 0.36 quality-adjusted life years.
  • Assumed a -0.8% reduction in glycated haemoglobin persisting for 5 years.

Conclusions:

  • Anti-CD3 monoclonal antibody treatment may improve life expectancy and quality-adjusted life expectancy.
  • Potential benefits include improved glycaemic control and preservation of beta-cell function.
  • This offers a potential advantage over conventional exogenous insulin therapy for newly diagnosed Type 1 diabetes.

More Related Videos

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

Related Concept Videos

Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...